Skip to main
CTSO
CTSO logo

CytoSorbents (CTSO) Stock Forecast & Price Target

CytoSorbents (CTSO) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

CytoSorbents Corp anticipates a growth in total revenue of 1.5%-2.5% year-over-year, an increase from earlier expectations of flat sales, indicating a positive trend in product demand. The company has demonstrated improved momentum with earnings beats in the second and third quarters, suggesting a strengthening financial position, particularly through the successful expansion of its Nordstrom Rack business. Additionally, the liquidity boost of approximately $12.3 million from the January 2025 fundraising effort positions CytoSorbents favorably for strategic initiatives aimed at driving revenue growth and enhancing shareholder value in 2025.

Bears say

CytoSorbents Corp faces significant financial challenges that contribute to a negative outlook on its stock. The company has undergone gross margin pressure, which reflects difficulties in maintaining profitability despite an increase in topline revenue. Additionally, various external risks, such as volatile commodity costs, rising interest rates, and weaker consumer confidence, could further jeopardize CytoSorbents' financial stability and growth potential.

CytoSorbents (CTSO) has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CytoSorbents (CTSO) Forecast

Analysts have given CytoSorbents (CTSO) a Buy based on their latest research and market trends.

According to 10 analysts, CytoSorbents (CTSO) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CytoSorbents (CTSO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.